The latest price target for Bioventus (NASDAQ:BVS) was reported by Canaccord Genuity on November 6, 2024. The analyst firm set a price target for $15.00 expecting BVS to rise to within 12 months (a possible 30.32% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Bioventus (NASDAQ:BVS) was provided by Canaccord Genuity, and Bioventus maintained their buy rating.

The last upgrade for Bioventus Inc happened on December 7, 2023 when Canaccord Genuity raised their price target to $7. Canaccord Genuity previously had a hold for Bioventus Inc.

The last downgrade for Bioventus Inc happened on November 22, 2022 when Craig-Hallum changed their price target from N/A to N/A for Bioventus Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bioventus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bioventus was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Bioventus (BVS) rating was a maintained with a price target of $12.00 to $15.00. The current price Bioventus (BVS) is trading at is $11.51, which is out of the analyst’s predicted range.